Home » Search
Search Results
987 results for 'roche'
- Sort By
-
Date
- Any Time
- Past Day
- Past Week
- Past Month
- Past Year
-
Custom Date Range
Articles
Company news
Bring in the relationship experts to label this one. St. Vincent Health and Monroe Hospital in Bloomington have pulled back from their “strategic alignment”—which had St. Vincent managing Monroe’s operations but was a step short of a merger—and will instead settle for a clinical partnership for cardiology, orthopedic and critical care services. Longtime St. Vincent executive Joe Roche, who had led the attempt to integrate the systems, will now become the CEO of Monroe Hospital, starting Monday. “We are appreciative for the opportunity to have explored integration options with Monroe Hospital, and to continue our clinical partnerships to serve the residents of Bloomington and surrounding communities,” Ian Worden, interim CEO of St. Vincent Health, said in a prepared statement. The Bloomington market is dominated by St. Vincent’s archrival, Indianapolis-based Indiana University Health, which owns IU Health Bloomington Hospital there. Monroe, which boasts 32 inpatient beds, was having financial difficulties and had been looking at a partnership with Franciscan St. Francis Health before it struck its deal with St. Vincent last year.
Less-than-expected profit in emerging markets and a decline in the Japanese yen could make it difficult for Eli Lilly and Co. to meet a goal of at least $20 billion in revenue next year, the Indianapolis-based drugmaker said Thursday. But the company said it would cut costs, if necessary, to reach its other 2014 goals of $3 billion in profit and $4 billion in operating cash flow. “I am confident in our outlook to return to a period of growth and expanding margins,” Chief Financial Officer Derica Rice said in a statement. Lilly will also take a hit from Obamacare. The 2010 law, known as the Patient Protection and Affordable Care Act, required drugmakers to give larger rebates to federally funded health plans and will add a tax onto all U.S. sales of prescription drugs. Those impacts, as well as Obamacare's elimination of a tax benefit for retiree drug coverage, will cost Lilly about $500 million this year. But Lilly might also see its sales hampered by the Obamacare exchanges, the online marketplaces that started Tuesday in all 50 states. That's because health insurers, in an attempt to keep premiums low, are creating narrower formularies that exclude some drugs from coverage. Similarly, insurers are creating "narrow networks" that offer coverage for fewer doctors and hospitals.
Indiana University Health plans to eliminate 935 workers in Indianapolis, Carmel, Fishers and Muncie, according to documents filed by the hospital system with the state. The cuts will affect 746 in Indianapolis at Methodist Hospital, Riley Hospital for Children, University Hospital and IU Health Physicians. In Carmel, 67 will be cut at IU Health North Hospital. Two will be trimmed at Saxony Hospital in Fishers. In Muncie, IU Health plans 120 cuts at Ball Memorial Hospital. IU Health employs about 36,000 statewide. It says it's looking to save $1 billion in costs over the next four years. The Indianapolis-based system said last month it must make the cuts because fewer patients have been coming to hospitals, and payment rates for its services have been declining.
Local ad agency losing Simon work, cutting employees
Publicis Indianapolis, one of the top-billing agencies in the city, will lose about eight employees. President Tom Hirschauer will step down to become a consultant.
Technology on track to dramatically change health care
Cost pressures are forcing health care providers to extend the reach of limited resources.
Indians’ financial outlook sky high as attendance soars
The Indianapolis Indians finished their 2013 season with the highest overall regular-season attendance of all 176 Minor League Baseball teams. Profit this year could be double what it was just a few years ago.
Company news
The federal Medicare program has decided, at least for now, not to reimburse health care providers who conduct diagnostic imaging tests using an Eli Lilly and Co. imaging agent that can help identify the presence of Alzheimer’s disease. Medicare will pay for those scans if they are part of a clinical trial of a drug and will consider paying for broader use in the future. But Indianapolis-based Lilly, as well as the Chicago-based Alzheimer’s Association, had been hoping for wider reimbursement now. The Alzheimer’s Association noted that it typically takes seven years for a procedure to move from clinical-trial-only reimbursement to broad reimbursement. The narrower use of Lilly’s agent, which is called Amyvid, is a small hit financially for Lilly. The bigger impact is that Lilly hoped wide use of Amyvid could help it and other companies bring drugs to market to treat Alzheimer’s. Since there are currently no effective treatments for the disease, any drug that did help with treatment would be an instant blockbuster. Lilly’s experimental drug solanezumab could have sales topping $4 billion annually if it proves effective in patients with mild Alzheimer’s disease. The drug failed its clinical trials last year when tested in a mix of mild and moderate Alzheimer’s patients, but it showed encouraging results in patients with only mild Alzheimer’s disease. The only way to identify such patients is by using a special kind of imaging test that will show deposits of a protein called amyloid—which is one of two telltale signs of Alzheimer’s disease. The imaging test is called PET, or positron emission tomography. Before Amyvid, however, the only way to view these plaques was during an autopsy.
Cancer drug Erbitux, which is partly owned by Indianapolis-based Eli Lilly and Co., extended the lives of patients with a form of advanced colon cancer more than seven months longer than those taking Roche Holding AG’s Avastin, according to clinical trial results released Saturday. According to Bloomberg News, the results were presented at a scientific conference in Europe by Germany-based Merck KGaA, which sells the medicine outside North America. Lilly and New York-based Bristol-Myers Squibb Co. market the drug in the United States. Erbitux generated sales for Merck of $1.2 billion last year, while Lilly realized $400 million in revenue from the drug in 2012. According to Bloomberg, the findings suggest that Erbitux, already approved in Europe as a treatment for patients with so-called KRAS wild-type tumors, may have a role in a subgroup of patients with so-called RAS wild-type cancer.
Purdue University chemistry professor Graham Cooks, whose research has played a role in the launch of several Indiana startups, was awarded the 2013 Dreyfus Prize in Chemical Sciences, the highest award possible for a chemist, during a ceremony last week. Cooks won the prize and its $250,000 payment for his innovations in the fields of mass spectrometry and analytical chemistry. Cooks and his team have fine-tuned the tools for molecular imaging for cancer diagnostics and surgery; therapeutic drug monitoring; testing for biomarkers in urine; and the identification of food-borne pathogens, bacteria, pesticides and explosives residues. His research has contributed to the technology developed by Griffin Analytical Technologies Inc., Prosolia, Inc. and InProteo LLC.
In a big disappointment, Indianapolis-based Eli Lilly and Co. reported that its experimental cancer drug ramucirumab proved no better than a placebo as a treatment for breast cancer. According to the Associated Press, the Indianapolis-based firm no longer plans to seek regulatory approval for the drug as a treatment for patients with a form of breast cancer that has spread. However, Lilly will seek approval to use ramucirumab in combination with chemotherapy in stomach cancer patients after ramucirumab performed better in a separate study on those patients. Ramucirumab extended both overall and progression-free survival times for patients with advanced gastric cancer. Lilly will seek approval from regulators for that use. It also is studying ramucirumab in colorectal and lung cancers and expects more late-stage research results next year. Ramucirumab is one of Lilly’s best hopes to produce new revenue to offset the loss of sales it has been suffering since the 2011 patent expirations on its then-best-seller, Zyprexa, and the patent expiration coming at year’s end on its current best seller, Cymbalta.
Lilly drug beats Roche’s Avastin in advanced colon cancer
Cancer drug Erbitux extended the lives of patients with a form of advanced colon cancer more than seven months longer than those taking Roche Holding AG’s Avastin.
RCA brand lives on, sans Nipper and Chipper
In a plot right out of Jurassic Park, Thomson Consumer Electronics’ old brands such as RCA and Proscan have been revived from old DNA. They’ve been licensed to companies around the world including Indianapolis-based company that operates as RCA Commercial Electronics.
Alzheimer’s targeted in $45M government study grant
Part of the funding will go to an existing study of drugs from Eli Lilly and Co. and others to see whether they can ward off the disease in people who inherited genes that predestine them to get Alzheimer’s.
IBJ Real Estate Power Breakfast transcript
Indianapolis Business Journal gathered leaders in the state's commercial real estate and construction industry for a Power Breakfast panel discussion Sept. 13. The following is an unedited transcript of the discussion.
Entrepreneur not sold on flight times between Indy, San Francisco
The nonstop connection to Silicon Valley that Indianapolis’ tech community has been clamoring for is here, but a leading advocate for the service said it doesn’t meet his industry’s needs.
New gadget revives waterlogged cellphones
Joel Trusty realized that if he could remove all the atmospheric pressure from a chamber, he could turn liquid—even liquid inside a cell phone—into a gas at a much lower temperature than otherwise possible.
‘Prototyper’ sees business gain fizz
TWeatherford Inc. was launched in 2006 as a reseller for additive manufacturing equipment, often called 3D printers or rapid prototypers. It has done well with the machinery sales and rentals, but has begun providing actual manufacturing services on a larger scale.
Ballard wins allies for cricket strategy
Both sides of the political aisle are howling that the $6 million transforming Post Road Community Park into the Indianapolis World Sports Park could be better spent. Yet a powerful group of people and organizations says the 48-acre park championed by Mayor Greg Ballard is already paying off and will score even bigger dividends in the future.
Language Training Center plans expansion
Indianapolis-based Language Training Center Inc. plans a $1.5 million expansion that will lead to the hiring of 26 more employees by 2017, the company announced Thursday.
Indiana joins push to allow public body prayers
The Indiana attorney general's office last week signed onto a friend-of-the-court brief asking the U.S. Supreme Court to exempt public bodies from screening opening prayers for sectarian references.
Company news
Plunging revenue from blood glucose monitors has forced Roche Diagnostics Corp. to cut its staff, the company informed the workers last week. Roche, which operates its North American headquarters out of Indianapolis, suffered a 14-percent decline in revenue in its diabetes care unit during the first six months of the year. Roche has put that unit up for sale, according to a May report by the Reuters news agency. Roche spokesman Todd Siesky declined to disclose the number of workers that will be let go, only saying that jobs will be eliminated over the next several months. The cuts will affect Roche’s customer service group in Fishers and its diabetes manufacturing plant on the far northeast side. Between the two sites, Roche employs more than 900 diabetes care workers in the metro area. During the first six months of this year, Roche’s North American sales of diabetes products totaled $224 million. During the same period of 2012, diabetes sales in North American totaled about $257 million. And it’s going to get worse. The price of blood glucose monitors—which account for 90 percent of Roche’s diabetes care revenue—will be hammered by a new competitive bidding process instituted July 1 by the federal Medicare agency. Some projections indicated the Medicare program would drive down its payments 72 percent.
Indianapolis venture capitalist Matt Neff is the new CEO of Indianapolis-based AIT Laboratories, the drug-testing lab founded by Michael Evans. Evans stepped aside once before, in early 2012, and was replaced by Ron Thieme, who had been vice president of information technology. But the move didn’t work out, and Evans returned to the top job that fall. Now, Evans, 69, is stepping aside again, and Neff is becoming chairman, president and CEO, effective Monday. (See related story above.) Evans will remain chairman emeritus and continue as CEO of AIT sister company AIT Bioscience. Neff, meanwhile, is stepping down as CEO and president of CHV Capital, the venture capital arm of Indiana University Health, a post he held for six years. IU Health said the CHV Capital board would conduct a search for his replacement. AIT, founded in 1990 by Evans, then an Indiana University School of Medicine professor, caught fire about 10 years ago when it became the nation’s pioneer in urine drug tests to help doctors monitor patients taking narcotics for chronic pain. But AIT has been in turnaround mode after failing to respond quickly to deep cuts in Medicare reimbursement rates for basic drug tests. In 2009, Evans sold the company to employees for $90 million, with payments to him staggered over a number of years.
Community Health Network and Johnson Memorial Health opened the doors to a new health pavilion that will house doctors from both Community Physician Network and Johnson Memorial Physician Network, including specialists in family medicine, pediatrics, orthopedics, women’s health and general surgery. The facility will also offer walk-in lab testing, an imaging center, and physical and occupational therapy. Indianapolis-based Community and Franklin-based Johnson Memorial formed a partnership two years ago.
Roche to cut local jobs after diabetes-care sales plunge
Roche’s diabetes care unit, which employs more than 900 in Indianapolis, suffered a 14-percent decline in revenue during the first half of 2013. Roche has reportedly put the unit up for sale.
Delta Faucet builds innovation machine in Carmel
One of Indiana’s most innovative companies in the past decade doesn’t make surgical instruments or drugs or engines. It makes water faucets and toilets. Delta Faucet Co. has secured 589 patents in the past 20 years.
MAURER: Good jobs build civic pride
Businesses across a broad spectrum are adversely affected when a headquarters is lost. Our firms suffer when goods and services are no longer purchased locally. The mediocre occupancy rate in downtown office space is a direct result of vanishing downtown headquarters.